MedTrace Logo

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

NCT01199341 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-02-09

No results posted yet for this study

Summary

The primary purpose of this study is to determine whether the treatment with AZD1981 affect the exposure of Warfarin.

Conditions

  • Pharmakokinetic

Interventions

DRUG

AZD1981

100 mg per oral, twice daily for 14 days

DRUG

Warfarin

10 x 2.5 mg per oral, once daily at day 1 and day 15

DRUG

AZD1981

4 x 100 mg per oral, twice daily for 14 days

Sponsors & Collaborators

Principal Investigators

  • Christer Hultqvist, MD · AstraZeneca

  • Aslak Rautio · Quintiles AB

  • Wofgang Kühn, MD · Quintiles AB

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199341 on ClinicalTrials.gov